Thomas Hemphill

True to President Donald Trump’s campaign promise to reduce the federal government’s regulatory burden on the nation’s manufacturers, the performance of the first two years of the Trump administration appears to have met with this sector’s general approval.

The ongoing controversy over e-cigarettes and youth smoking has hit a proverbial regulatory wall.

In March, Reps. Steve Stivers, R-Ohio, and Bill Foster, D-Illinois, introduced the Support Technology & Research for Our Nation’s Growth and Economic Resilience (STRONGER) Patents Act of 2018.

Since Elaine Herzberg’s death last month when an Uber autonomous test vehicle struck and killed her in Tempe, Arizona, we have learned more information about this tragic incident.

Generic drugs make up about 88 percent of prescriptions filled in the United States, providing generally low-cost relief for the overwhelming majority of Americans who are presently afflicted with a variety of health-related maladies.

On May 26, Maryland became the first state to pass a law which applies specifically to “price gouging” practices by generic pharmaceutical manufacturers of essential drugs.

In President Donald Trump’s “Contract with the American Voter”, a key component is a pledge to reduce the regulatory burden on businesses, their employees, and consumers, and there appears to be solid public support for this policy change.

Cities across the nation have passed tax increase on sugar content in sweetened beverages. Despite the good intentions, research has shown efforts by companies have already reduced sugar and offered alternative options to informed consumers, making them unnecessary.

The road ahead may be bumpy, but there’s no going back.

The Ewing Marion Kaufman Foundation, a Missouri-based nonprofit organization at the forefront of supporting research on entrepreneurship and innovation in the United States, recently published a policy paper titled “A…